Future studies will be needed to identify the mechanisms that influence CD38 expression in SLE as well as the pathogenic role of cells with increased CD38 expression, especially in light of anti-CD38 monoclonal antibodies being an emerging plasma cell-targeting therapy in SLE. The gene discussed is CD38; the disease is systemic lupus erythematosus.